Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

CERO

CERo Therapeutics Holdings Inc.

Jun 14 • 04:00PM ET

0.3799

Dollar change +0.0203
Percentage change 5.65	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.46	Insider Own	53.66%	Shs Outstand	15.06M	Perf Week	-43.57%
Market Cap	5.72M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	6.98M	Perf Month	-67.08%
Income	-4.34M	PEG	-	EPS next Q	-	Inst Own	0.47%	Short Float	1.65%	Perf Quarter	-82.33%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	6.19%	Short Ratio	0.11	Perf Half Y	-96.52%
Book/sh	-0.74	P/B	-	EPS next Y	-	ROA	-33.39%	Short Interest	0.12M	Perf Year	-96.29%
Cash/sh	0.30	P/C	1.25	EPS next 5Y	-	ROE	-1708.01%	52W Range	0.33 - 12.80	Perf YTD	-96.55%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-97.03%	Beta	-0.35
Dividend TTM	-	Quick Ratio	0.47	Sales past 5Y	0.00%	Gross Margin	-	52W Low	15.09%	ATR (14)	0.15
Dividend Ex-Date	-	Current Ratio	0.47	EPS Y/Y TTM	-317.91%	Oper. Margin	0.00%	RSI (14)	20.44	Volatility	50.65% 20.45%
Employees	9	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-119.66%	Payout	-	Rel Volume	4.35	Prev Close	0.36
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	1.08M	Price	0.38
SMA20	-57.34%	SMA50	-69.83%	SMA200	-94.57%	Trades		Volume	4,685,802	Change	5.65%

Jun-13-24 08:15AM	CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236 (GlobeNewswire) -48.86%
Jun-06-24 10:15AM	Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy (ACCESSWIRE) -16.47%
08:00AM	CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236 (GlobeNewswire)
May-15-24 08:00AM	CERo Therapeutics, Inc. Provides Corporate Update for Shareholders (GlobeNewswire)
Apr-30-24 09:00AM	CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes (GlobeNewswire)
07:00AM	Loading…
Mar-07-24 07:00AM	CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients (Business Wire) +20.78%
Feb-14-24 04:48PM	Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination (Business Wire)
Jun-05-23 08:00AM	CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics (Business Wire)

CERo Therapeutics Holdings, Inc. is a blank check company, formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on June 8, 2021 and is headquartered in Oakland, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CERO

CERo Therapeutics Holdings Inc.

Upgrade your FINVIZ experience